Cardiovascular medications in angiogenesisuHow to avoid the sting in the tail

被引:9
|
作者
Ma, Chenming
Wang, Qing
Man, Yicun
Kemmner, Wolfgang
机构
[1] Max Delbrueck Ctr, Expt & Clin Res Ctr, Res Grp Surg Oncol, Berlin, Germany
[2] Charite Campus Buch, Berlin, Germany
关键词
angiogenesis; cancer; cardiovascular disease; aspirin; ss-blocker; statin; ACEI; ARB; ANGIOTENSIN-CONVERTING-ENZYME; ENDOTHELIAL-GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; II TYPE-1 RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARTERIAL THROMBOEMBOLIC EVENTS; ISCHEMIA-INDUCED ANGIOGENESIS; HEART-RATE REDUCTION; SMOOTH-MUSCLE-CELLS; CORONARY ANGIOGENESIS;
D O I
10.1002/ijc.27576
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer and cardiovascular disease are the leading causes of death worldwide. Cardiovascular medications have recently been found to have favorable effects also for the treatment of noncardiovascular diseases, including cancer. In this review, we use a reverse bedside-to-bench approach to investigate the effects of common cardiovascular medications on tumor angiogenesis and vascular angiogenesis. Aspirin seems to reduce the risk of developing cancer, particularly colon cancer. However, whether the protective influence of aspirin is due to antiangiogenesis effect is still unclear. beta-Blockers, which are normally used to reduce heart rate and prolong diastole, trigger an increase in stretch-associated release of proangiogenic growth factors thereby inducing angiogenesis. However, according to other studies beta-blockers are able to inhibit angiogenesis via multiplicate mechanisms. Similarly, angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor blocker have controversial effects for the regulation of cell proliferation and angiogenesis. Statins can augment collateral vascular growth in ischemic tissues and restrict the development of cancer. So this topical anti-inflammatory drug seems to be of high value for further therapy. Finally, suggestions on how this pilot experience may guide the conduct of future preclinical investigations, and clinical trials are discussed.
引用
收藏
页码:1249 / 1259
页数:11
相关论文
共 50 条
  • [31] Todralazine hepatotoxicity: A sting in the histone tail
    Elsharkawy, Ahmed M.
    JOURNAL OF HEPATOLOGY, 2007, 46 (02) : 189 - 192
  • [32] A STING IN THE (M-TERMINAL) TAIL
    ARTYMIUK, PJ
    NATURE STRUCTURAL BIOLOGY, 1995, 2 (12): : 1035 - 1037
  • [33] YAP/TAZ get a STING in the tail
    Paulina Strzyz
    Nature Reviews Molecular Cell Biology, 2022, 23 : 581 - 581
  • [34] A nuclear STING in the tail for canonical signalling
    Kirsty Minton
    Nature Reviews Immunology, 2024, 24 : 1 - 1
  • [35] Viral infection has a sting in the tail
    Muers, Mary
    NATURE REVIEWS GENETICS, 2009, 10 (07) : 428 - 428
  • [36] Costing IS services - Avoiding the sting in the tail
    Altmann, G
    Norris, G
    Pigdon, M
    CHALLENGES OF INFORMATION TECHNOLOGY MANAGEMENT IN THE 21ST CENTURY, 2000, : 11 - 15
  • [37] The sting in the tail: antiseptics and the neuraxis revisited
    Bogod, D.
    ANAESTHESIA, 2012, 67 (12) : 1305 - 1309
  • [38] Pet Medications: A Tail of Caution
    Nguyen, Tammy T.
    Kirkwood, Craig F.
    Reilly, Denise
    Lee, Danyae
    Coggin, Christy
    JOURNAL OF PHARMACY PRACTICE, 2022, 35 (02) : 317 - 321
  • [39] CARDIOVASCULAR MEDICATIONS
    ICE, D
    PHYSICAL THERAPY, 1985, 65 (12): : 1845 - 1855
  • [40] Medications: Do Good and Avoid Bad
    Maxson, Rebecca
    PHYSICIAN ASSISTANT CLINICS, 2023, 8 (02) : XVII - XIX